Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23218304 | 0.77 | ESR2 (0.39) | ALDH1A1MAOBSMN1; SMN2CYP1A2KDM4E | |
| SCHEMBL16005132 | 0.77 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL29558872 | 0.77 | CYP1A2 (0.44) | ALDH1A1EGFRKDRSMN1; SMN2CYP1A1 | |
| SCHEMBL24947178 | 0.77 | CYP1A2 (0.44) | ALDH1A1EGFRKDRSMN1; SMN2CYP1A1 | |
| SCHEMBL23218427 | 0.74 | ALDH1A1 (0.45) | ALDH1A1EGFRKDRSMN1; SMN2KDM4E | |
| SCHEMBL20562110 | 0.74 | KDM4E (0.44) | ALDH1A1EGFRKDRMAOASMN1; SMN2 | |
| SCHEMBL2152858 | 0.73 | ESR1 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL29784457 | 0.73 | LOXL2 (0.53) | — | |
| SCHEMBL3603150 | 0.73 | CYP11B1 (0.39) | ALDH1A1EGFRKDRKDM4EHPGD | |
| SCHEMBL27185532 | 0.73 | LOXL2 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3653613-B1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | BEBETTER MED INC (CN) | 2022-11-16 | — | — | EP | disclosed |
| US-11306102-B2 | 1,3-di-substituted ketene compound and application thereof | BEBETTER MED INC. (CN) | 2022-04-19 | — | — | US | disclosed |
| US-20210122761-A1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | BEBETTER MED INC. (CN) | 2021-04-29 | — | — | US | disclosed |
| EP-3653613-A1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | Guangzhou Bebetter Medicine Technology Co., Ltd. (CN) | 2020-05-20 | — | — | EP | disclosed |
| CN-108658908-B | 1,3- bis- replaces ketene compounds and its application | 广州必贝特医药技术有限公司 | 2019-05-10 | — | — | CN | disclosed |
| CN-108658908-A | 1,3- bis- substitution ketene compounds and its application | 广州必贝特医药技术有限公司 | 2018-10-16 | — | — | CN | disclosed |
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-0906301-B1 | BENZOFURYL DERIVATIVES AND THEIR USE | HOFFMANN LA ROCHE (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-5955495-A | BENZOFURAN-2-CARBOXAMIDINE OR 2-CARBOXAMIDOXIME COMPOUNDS USEFUL IN THE CONTROL OR PREVENTION OF ILLNESSES OR DISORDERS OF THE CENTRAL NERVOUS SYSTEM SUCH AS MIGRAINE, SCHIZOPHRENIA, ANXIETY STATES, SLEEP DISORDERS, ANOREXIA, ALZHEIMER'S | HOFFMANN-LA ROCHE INC. (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0906301-A1 | BENZOFURYL DERIVATIVES AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997042183-A1 | BENZOFURYL DERIVATIVES AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | ALDH1A1 1763/4885EGFR 557/4885KDR 799/4885 |
| US-20210122761-A1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | PPARA, FABP1, PPARG | ALDH1A1 1018/4885EGFR 1832/4885KDR 575/4885 |
| US-11306102-B2 | 1,3-di-substituted ketene compound and application thereof | PPARA, FABP1, PPARG | ALDH1A1 1018/4885EGFR 1832/4885KDR 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.